Modulation of Multidrug Resistance in Human Renal Cell Carcinomas

  • G. H. Mickisch
  • P. M. Alken
Conference paper


Intrinsic chemoresistance has major impact on the dismal prognosis of patients with disseminated renal cell carcinoma (RCC) in the absence of reliable therapeutic alternatives [27]. P-170 glycoprotein was identified as a putative mechanism conferring drug resistance. Recently, a high expression of MDR 1 gene mRNA [13] as well as of P-170 glycoprotein [17–19] was traced in human RCCs, which may partially explain the high degree of de novo resistance. Calcium antagonists (CAs) are substances which interfere with the calcium intake at the cytoplasmatic membrane. They are mainly employed in the treatment of cardiovascular disorders such as hypertension, arrhythmia and angina pectoris. Lately, the interaction of CAs with chemotherapeutics to enhance cytotoxicity has gained particular interest. It has been shown that CAs reverse acquired resistance of experimental animal tumors [25] to some anticancer drugs and increase the life span of tumor-bearing animals compared to those merely treated with vinca alkaloids [21].


Renal Cell Carcinoma Calcium Antagonist Vinca Alkaloid Viable Tumor Cell Human Renal Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alley MC, Scudiero DA, Monks A, et al. (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589–601PubMedGoogle Scholar
  2. 2.
    Baeyens JM (1988) Interactions between calcium channel blockers and non-cardiovascular drugs: Interactions with anticancer drugs. Pharmacol Toxicol 63: 1–7PubMedCrossRefGoogle Scholar
  3. 3.
    Broxterman HJ, Pinedo HM, Kuiper CM, et al. (1989) Immunohistochemical detection of P-glycoprotein in human tumor cells with a low degree of drug resistance. Int J Cancer 43: 340–341PubMedCrossRefGoogle Scholar
  4. 4.
    Cantwell B, Puamah P, Harris AL (1985) Phase I and phase II study of oral verapamil (VRP) and intravenous vindesine (VDN). Br J Cancer 52: 425Google Scholar
  5. 5.
    Dalton WS, Grogan TM, Meltzer PS, et al. (1989) Drug-resistance in multiple myeloma and non-Hodgkin’s Lymphoma: Detection of Pglycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415–424PubMedGoogle Scholar
  6. 6.
    Echizen H, Brecht T, Niedergesaess S, Vogelgesang B, Eichelbaum M (1985) The effect of dextro-laevo-and racemic verapamil on atrio-ventricular conduction in humans. Am Heart J 109: 210–217PubMedCrossRefGoogle Scholar
  7. 7.
    Eichelbaum M, Birkel P, Grube E, Gutgemann U, Somerogyi A (1980) Effects on P-R intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment. Klin Wochenschr 58: 919–925PubMedCrossRefGoogle Scholar
  8. 8.
    Hamann SR, Blouin RA, McAllister Jr RG (1984) Clinical pharmacokinetics of verapamil. Clinical Pharmacokinetics 9: 26–41PubMedCrossRefGoogle Scholar
  9. 9.
    Hermanek P (1987) UICC, TNM Classification of malignant tumors, 4th edn. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  10. 10.
    Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6: 65–70Google Scholar
  11. 11.
    Ince P, Appleton DR, Finney KJ, Sunter JP, Watson AJ (1986) Verapamil increases the sensitivity of primary human colorectal carcinoma tissue to vincristine. Br J Cancer 53: 137–139PubMedCrossRefGoogle Scholar
  12. 12.
    Kaba K, Tanki E, Morimura T, Matsumoto T (1985) Potentiation of vincristine effects in human and murine gliomas by calcium channel blockers or calmodulin inhibitors. J Neurosurg 63: 905–911PubMedCrossRefGoogle Scholar
  13. 13.
    Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman MM, Pastan I (1988) Measurements of multidrug resistance messenger-RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 139: 862–865PubMedGoogle Scholar
  14. 14.
    Kanamaru H, Kakehi Y, Yoshia O, Nakanishi S, Pastan I, Gottesman MM (1989) MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst 81: 844–849PubMedCrossRefGoogle Scholar
  15. 15.
    Kartner N, Evernden-Porelle D, Bradley G, Ling V (1985) Detection of P-170 glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316: 820–823PubMedCrossRefGoogle Scholar
  16. 16.
    Mickisch G, Fajta S, Keilhauer G, Schlick E, Tschada R, Alken P (1990) Chemosensitivity testing of primary human renal cell carcinoma by a tetrazolium based microculture assay (MTT). Urol Res 18: 131–136PubMedCrossRefGoogle Scholar
  17. 17.
    Mickisch G, Bier H, Bergler W, Bak M, Tschada R, Alken P (1990) P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. Urol Intern 45: 170–176CrossRefGoogle Scholar
  18. 18.
    Mickisch G, Kössig J, Keilhauer G, Schlick E, Tschada R, Alken P (1990) Effects of calcium antagonists in multidrug resistant primary human renal call carcinomas. Cancer Res 50: 3670–3674PubMedGoogle Scholar
  19. 19.
    Mickisch G, Röhrich K, Kössig J, Forster S, Tschada R, Alken P (1990) Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. J Urol 144: 755–759PubMedGoogle Scholar
  20. 20.
    Milroy R, Connory L, Banham F, Hutcheon D, Maclntyre D, Stack B (1987) Randomized trial of verapamil in addition to chemotherapy for small cell lung cancer. Thorax 42: 209Google Scholar
  21. 21.
    Morrow M, Wait RB, Rosenthal RA, Gamelli RL (1987) Verpamil enhances antitumor activity without increasing myeloid toxicity. Surgery 101: 63–65PubMedGoogle Scholar
  22. 22.
    Ozols RF, Cunnian RE, Klecker RW, Hamilton FC, Ostchega Y, Parillo JE, Young RC (1987) Verapamil and adriamycine in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5: 641–647PubMedGoogle Scholar
  23. 23.
    Paoletti R, Govoni S (1987) Classification of calcium antagonists: Proposal of the WHO Committee. Pharmacol Res Comm Vol. 19, 3: 195–209CrossRefGoogle Scholar
  24. 24.
    Simmonds AP, Moyes P, Nicol A, Davidson KG, Faichney A (1986) Enhancement of cytotoxicity of vindesine and cis-platinum for human lung tumours by the use of verapamil in vitro. Br J Cancer 54: 1015–1018PubMedCrossRefGoogle Scholar
  25. 25.
    Tsuruo T (1983) Reversal of acquired resistance to vinca alcaloids and anthracycline antibiotics. Cancer Treat Rep 67: 889–894PubMedGoogle Scholar
  26. 26.
    Tsuruo T (1988) Mechanisms of multidrug resistance and implications for therapy. Jpn J Cancer Res (Gann) 79: 285–296CrossRefGoogle Scholar
  27. 27.
    Vugrin D (1987) Systematic therapy of metastatic renal cell carcinoma. Sem Nephrol 7: 152–162Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • G. H. Mickisch
    • 1
  • P. M. Alken
    • 2
  1. 1.Laboratory of Molecular Biology, National Cancer InstituteNational Institutes of HealthBethesdaUSA
  2. 2.Urologische KlinikKlinikum Mannheim der Universität HeidelbergMannheimGermany

Personalised recommendations